

Migraine

REFERENCES

- Bartleson JD. Treatment of migraine headaches. *Mayo Clin Proc* . 1999 Jul;74(7):702–8.
- Beckett BE, Herndon KC. Headache disorders. In: Dipro JT, Talbert RL, et al, eds. *Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill; 2002:1119–35.
- Beckham JC, Krug LM, et al. The relationship of ovarian steroids, headache activity and menstrual distress: A pilot study with female migraineurs. *Headache* . 1992 Jun;32(6):292–7.
- Behmand RA, Tucker T, et al. Single-site botulinum toxin type a injection for elimination of migraine trigger points. *Headache* . 2003 Nov;43(10):1085–9.
- Binder WJ, Blitzer A. Treatment of migraine headache with botulinum toxin type A. *Facial Plast Surg Clin North Am* . 2003 Nov;11(4):465–75.
- Boehnke C, Reuter U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: An open study in a tertiary care centre. *Eur J Neurol* . 2004 Jul;11(7):475–7.
- Breslau N, Andreski P. Migraine, personality, and psychiatric comorbidity. *Headache* . 1995 Jul;35(7):382–6.
- Breslau N, Rasmussen BK. The impact of migraine: Epidemiology, risk factors, and co-morbidities. *Neurology* . 2001;56(6 Suppl 1):S4–S12.
- Brune K, Bickel D, et al. Gastro-protective effects by extracts of *Petasites hybridus*: The role of inhibition of peptido-leukotriene synthesis. *Planta Med* . 1993 Dec;59(6):494–6.
- Chavanu KJ, O'Donnell DC. Hormonal interventions for menstrual migraines. *Pharmacotherapy* . 2002 Nov;22(11):1442–57.
- Claustrat B, Brun J, et al. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. *Cephalalgia* . 1997 Jun;17(4):511–7.
- Claustrat B, Loisy C, et al. Nocturnal plasma melatonin levels in migraine: A preliminary report. *Headache* . 1989 Apr;29(4):242–5.
- Cordivari C, Misra VP, et al. New therapeutic indications for botulinum toxins. *Mov Disord* . 2004 Mar;19 Suppl 8:S157–S161.
- Davey G, Sedgwick P, et al. Association between migraine and asthma: Matched case-control study. *Br J Gen Pract* . 2002 Sep;52(482):723–7.
- Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: A comparative review. *J Clin Pharmacol* . 2000 Jul;40(7):687–700.
- de Weerd GJ, Bootsman HPR, et al. Herbal medicines in migraine prevention: Randomized double-blind, placebo-controlled, crossover trial of a feverfew preparation. *Phytomedicine* . 1996;3:225–30.
- Diamond S, Wenzel R. Practical approaches to migraine management. *CNS Drugs* . 2002;16(6):385–403.
- Diener HC, Rahlfs VW, et al. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: Reanalysis of efficacy criteria. *Eur Neurol* . 2004;51(2):89–97.
- Dodick D, Blumenfeld A, et al. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. *Clin Dermatol* . 2004 Jan;22(1):76–81.

Dzugas SA, Smith RA. The simultaneous restoration of neurohormonal and metabolic integrity as a very promising method of migraine management. *Bull Urg Rec Med* . 2003;4(4):622–8.

Elsayed NM , Bendich A. Dietary antioxidants: Potential effects on oxidative products in cigarette smoke. *Nut Res* . 2001;21:551–67.

Gagnier JJ. The therapeutic potential of melatonin in migraines and other headache types. *Altern Med Rev* . 2001 Aug;6(4):383–9.

Gobel H. Botulinum toxin in migraine prophylaxis. *J Neurol* . 2004 Feb;251(Suppl 1):18–21

Grossman W, Schmidramsl H. An extract of *Petasites hybridus* is effective in the prophylaxis of migraine. *Altern Med Rev* . 2001 Jun;6(3):303–10.

Gruener G, Jay W. Treatment of headache with botulinum toxin administration. *Semin Ophthalmol* . 2003 Dec;18(4):200–4.

Henry P, Michel P, et al. A nationwide survey of migraine in France : Prevalence and clinical features in adults. *Cephalalgia* . 1992 Aug;12(4):229–37.

Hodson J, Thompson J, et al. Headache at menopause and in hormone replacement therapy users. *Climacteric* . 2000 Jun;3(2):119–24.

Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of *Tanacetum parthenium* L. extract in mice and rats. *J Ethnopharmacol* . 1999 Dec 15;68(1–3):251–9.

Johnson ES, Kadam NP, et al. Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J (Clin Res Ed)* . 1985 Aug 31;291(6495):569–73.

Joubert J. Diagnosing headache. *Aust Fam Physician* . 2005 Aug;34(8):621–5.

Kasper DL, Braunwald DE , et al. *Harrison's Principles of Internal Medicine* . 16th ed . New York : McGraw-Hill Professional; 2005.

Klapper J, Stanton J. The emergency treatment of acute migraine headache: A comparison of intravenous dihydroergotamine, dexamethasone, and placebo. *Cephalalgia* . 1991;11(suppl 11):159–60.

Ko WC, Lei CB, et al. Mechanisms of relaxant action of S-petasin and S-isopetasin, sesquiterpenes of *Petasites formosanus*, in isolated guinea pig trachea. *Planta Med* . 2001 Apr;67(3):224–9.

Lawrence EC. Diagnosis and management of migraine headaches. *South Med J* . 2004 Nov;97(11):1069–77.

Lim C. Headache, migraine. In: Ferri FF, ed. *Ferri's Clinical Advisor: Instant Diagnosis and Treatment*. Philadelphia , PA : Mosby; 2005:353–4.

Lipton RB, Gobel H, et al. *Petasites hybridus* root (butterbur) is an effective preventive treatment for migraine. *Neurology* . 2004 Dec 28;63(12):2240–4.

Lipton RB, Hamelsky SW, et al. Epidemiology and impact of headache In: Silberstein SD , eds. *Wolff's Headache and Other Head Pain*. New York : Oxford University Press; 2001:85–107.

Maizels M, Geiger AM. Intranasal lidocaine for migraine: A randomized trial and open-label follow-up. *Headache* . 1999 Sep;39(8):543–51.

Maizels M, Scott B, et al. Intranasal lidocaine for treatment of migraine: A randomized, double-blind, controlled trial. *JAMA* . 1996 Jul 24;276(4):319–21.

Martin VT, Wernke S, et al. Defining the relationship between ovarian hormones and migraine headache. *Headache* . 2005 Oct;45(9):1190–1201.

Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. *Clin Neurosci* . 1998;5(1):24–7.

Mauskop A, Altura BT, et al. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized

magnesium levels: A pilot study. *Clin Sci (Lond)* . 1995 Dec;89(6):633–6.

Misakian AL, Langer RD , et al. Postmenopausal hormone therapy and migraine headache. *J Womens Health (Larchmt)* . 2003 Dec;12(10):1027–36.

Murch SJ, Simmons CB, et al. Melatonin in feverfew and other medicinal plants. *Lancet* . 1997 Nov 29;350(9091):1598–9.

Murphy JJ, Heptinstall S, et al. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. *Lancet* . 1988 Jul 23;2(8604):189–92.

National Headache Foundation. *Migraine Headaches and Treatment* . National Headache Foundation; 2004.

Palevitch D, Earon G, et al. Feverfew (tanacetum parthenium) as a prophylactic treatment for migraine: A double-blind, placebo-controlled study. *Phytotherapy Res* . 1997;11:508–11.

Peatfield RC, Olesen J. Migraine: Precipitating factors. In: Olesen J, Tfelt-Hansen P, et al, eds. *The Headaches*. New York : Raven Press; 1993:241–5.

Peres MF, Zukerman E, et al. Melatonin, 3 mg, is effective for migraine prevention. *Neurology* . 2004 Aug 24;63(4):757.

Pfaffenrath V, Diener HC, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: A double-blind, multicentre, randomized placebo-controlled dose-response study. *Cephalalgia* . 2002 Sep;22(7):523–32.

Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. *Cephalalgia* . 1995 Oct;15(Suppl 15):14–20.

Pittler MH, Ernst E. Feverfew for preventing migraine. *The Cochrane Database of Systematic Reviews* . 2004;(Issue 1)

Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. *J Pharm Pharmacol* . 1988 Oct;40(10):743–5.

Rang HP, Dale MM, et al. *Pharmacology*. New York : Churchill Livingstone; 2005.

Recober A, Geweke LO. Menstrual migraine. *Curr Neurol Neurosci Rep* . 2005 Mar;5(2):93–8.

Rozen TD, Oshinsky ML, et al. Open label trial of coenzyme Q10 as a migraine preventive. *Cephalalgia* . 2002 Mar;22(2):137–41.

Sandor PS, Afra J, et al. Prophylactic treatment of migraine with beta-blockers and riboflavin: Differential effects on the intensity dependence of auditory evoked cortical potentials. *Headache* . 2000 Jan;40(1):30–5.

Sandor PS, Di CL, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. *Neurology* . 2005 Feb 22;64(4):713–5.

Scheidegger C, Dahinden C, et al. Effects of extracts and of individual components from Petasites on prostaglandin synthesis in cultured skin fibroblasts and on leucotriene synthesis in isolated human peripheral leucocytes. *Pharm Acta Helv* . 1998 Feb;72(6):376–8.

Schim J. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients. *Curr Med Res Opin* . 2004 Jan;20(1):49–53.

Schoenen J, Jacquy J, et al. Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. *Neurology* . 1998 Feb;50(2):466–70.

Schoenen J, Lenaerts M, et al. High-dose riboflavin as a prophylactic treatment of migraine: Results of an open pilot study. *Cephalalgia* . 1994 Oct;14(5):328–9.

Silberstein SD. Migraine symptoms: Results of a survey of self-reported migraineurs. *Headache* . 1995a Jul;35(7):387–96.

Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. *Headache* . 1997;37(Suppl 1):S15–S25.

Silberstein SD , Goadsby PJ, et al. Management of migraine: An algorithmic approach. *Neurology* . 2000a;55(9 Suppl 2):S46–S52.

Silberstein SD , Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. *Neurology* . 2000b Apr 25;54(8):1553.

Silberstein SD , Young WB. Migraine aura and prodrome. *Semin Neurol* . 1995b Jun;15(2):175–82.

Silberstein SD , Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. *Neurology* . 1995c Mar;45(3 Pt 1):577–84.

Silberstein SD , Young WB. Headache and facial pain. In: Goetz CG, ed. *Textbook of Clinical Neurology*. Philadelphia , PA : Elsevier Science (USA); 2003:1187–1206.

Smuts JA, Schultz D, et al. Mechanism of action of botulinum toxin type A in migraine prevention: A pilot study. *Headache* . 2004 Sep;44(8):801–5.

Spierings EL. Pathogenesis of the migraine attack. *Clin J Pain* . 2003 Jul;19(4):255–62.

Thomet OA, Wiesmann UN, et al. Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in human eosinophils. *Clin Exp Allergy* . 2001a Aug;31(8):1310–20.

Thomet OA, Wiesmann UN, et al. Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus. *Biochem Pharmacol* . 2001b Apr 15;61(8):1041–7.

Wang F, Van Den Eeden SK, et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: A randomized, double-blind, placebo-controlled trial. *Headache* . 2003 Jun;43(6):601–10.

Wang GJ, Shum AY, et al. Calcium channel blockade in vascular smooth muscle cells: Major hypotensive mechanism of S-petasin, a hypotensive sesquiterpene from *Petasites formosanus*. *J Pharmacol Exp Ther* . 2001 Apr;297(1):240–6.

Williams CA, Houtt JR, et al. A biologically active lipophilic flavonol from *Tanacetum parthenium*. *Phytochemistry* . 1995 Jan;38(1):267–70.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

LifeExtension®

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.